Crenarchaeal PCNA is known to consist of three subunits (PCNA1, PCNA2 and PCNA3) that form a heterotrimer (PCNA123). Recently, another heterotrimeric PCNA composed of only PCNA2 and PCNA3 was identified in Sulfolobus tokodaii strain 7 (stoPCNAs). In this study, the purified stoPCNA2-stoPCNA3 complex was crystallized by hanging-drop vapour diffusion. The crystals obtained belonged to the orthorhombic space groups I222 and P2 1 2 1 2, with unit-cell parameters a = 91.1, b = 111.8, c = 170.9 Å and a = 91.1, b = 160.6, c = 116.6 Å , respectively. X-ray diffraction data sets were collected to 2.90 Å resolution for the I222 crystals and to 2.80 Å resolution for the P2 1 2 1 2 crystals.
Introduction
DNA metabolism is mediated by protein complexes that consist of various DNA-processing proteins. The DNA sliding-clamp family of proteins interact with various DNA-processing proteins and play a central role as a platform for these proteins on DNA (for a review, see Moldovan et al., 2007) . The DNA sliding-clamp family consists of -clamps in bacteria and proliferating cell nuclear antigens (PCNAs) in eukarya and archaea.
Crystal structures of DNA sliding clamps have been reported for Escherichia coli (Kong et al., 1992) , human (Gulbis et al., 1996) , Saccharomyces cerevisiae (Krishna et al., 1994) , Pyrococcus furiosus (Matsumiya et al., 2001) and Sulfolobus solfataricus (Williams et al., 2006) . Various structural components are known; for example, the bacterial -clamp forms a homodimer, eukaryotic PCNAs form homotrimers and both homotrimeric and heterotrimeric structures exist in archaea. Nevertheless, structural analysis of DNA sliding clamps has revealed that they all form similar ring-shaped structures. In addition, DNA sliding-clamp structures suggest that a positively charged central cavity formed by -helices associates with DNA and that DNA sliding clamps can slide freely on DNA. The interdomainconnecting loop (IDCL), which generally interacts with the DNAprocessing proteins through the main motif known as the PIP box, is located on the outer side of the DNA sliding clamp.
A PCNA-forming heterotrimer has been found in three crenarchaeal species [Sulfolobus solfataricus (ssoPCNAs; Dionne et al., 2003) , Aeropyrum pernix (apePCNAs; Imamura et al., 2007) and Sulfolobus tokodaii strain 7 (stoPCNAs; Lu et al., 2008) ]. Biochemical studies of the subunit interactions and complex formation indicate that the interactions between these subunits (PCNA1, PCNA2 and PCNA3) vary depending on the species. In S. solfataricus, ssoPCNA1 and ssoPCNA2 first form a stable heterodimer and then recruit ssoPCNA3. In S. tokodaii, stoPCNA3 interacts with the other subunits, while no interaction (or little affinity) is observed between stoPCNA1 and stoPCNA2. Similarly, in A. pernix apePCNA2 interacts with the other subunits, while no interaction (or little affinity) is observed between apePCNA1 and apePCNA3. Interestingly, stoPCNA2-stoPCNA3 and apePCNA2-apePCNA3 are able to form a heterotrimer without the respective PCNA1s. Furthermore, the heterotrimer stoPCNA2-stoPCNA3 enhances the activity of Hjc and reduces the activity of Hjm and DNA ligase I like stoPCNA123 and the heterotrimer apePCNA2-apePCNA3 enhances the activities of DNA polymerase, DNA ligase I and Fen1 like apePCNA123. However, the detailed functional and structural differences between PCNA123 and PCNA2-PCNA3 remain to be clarified.
The present paper describes the purification, crystallization and preliminary X-ray analysis of the stoPCNA2-stoPCNA3 complex. A three-dimensional structural study of the PCNA2-PCNA3 complex is anticipated to be able to help in understanding the structural and functional differences between PCNA123 and PCNA2-PCNA3.
Methods

Protein expression and purification
Recombinant stoPCNA2 and stoPCNA3 proteins were individually overexpressed in Escherichia coli BL21 (DE3) using the pET expression system (Novagen). The transformant cells were grown to an OD 600 of 0.6 at 310 K in Luria-Bertani broth and 20%(w/v) lactose solution was added to give a final concentration of 1 mM. The cultures were grown for 4 h at 310 K and harvested by centrifugation (6500g for 20 min). The cells were resuspended in 20 mM Tris-HCl pH 8.0 and disrupted by sonication followed by incubation at 343 K for 30 min. After centrifugation (7000g for 30 min), ammonium sulfate was added to the supernatant to 45% saturation. After gentle stirring for 1 h at 277 K, the suspension was centrifuged (18 000g for 30 min) and ammonium sulfate was once again added to the supernatant to 65% saturation. After gentle stirring for 1 h at 277 K, the suspension was centrifuged (18 000g for 1 h) and the supernatant was removed. The precipitants were dissolved in 20 mM Tris-HCl pH 8.0 and the solution was dialyzed overnight against 1 l 20 mM Tris-HCl pH 8.0. Further purification was performed on a HiTrap Q anionexchange column (GE Healthcare); the proteins were eluted using a linear gradient from 0 to 0.5 M NaCl in 20 mM Tris-HCl pH 8.0. The fractions containing stoPCNA as judged by SDS-PAGE analysis were dialyzed overnight against 1 l 20 mM Tris-HCl pH 8.0 and concentrated. The stoPCNA2-stoPCNA3 complex was formed by incubating the proteins in an equal molar ratio at 277 K overnight and was purified by gel filtration on a Superdex 75 pg column (GE Healthcare) in 20 mM Tris-HCl pH 8.0 containing 150 mM NaCl. The peak fractions containing the stoPCNA2-stoPCNA3 complex were collected and concentrated to 40 mg ml À1 for crystallization trials.
Crystallization
Initial crystallization screening of the stoPCNA2-stoPCNA3 complex was performed by the sitting-drop vapour-diffusion method using the Index, Crystal Screen and Crystal Screen 2 crystal screening kits (Hampton Research). Equal volumes (1.2 ml) of protein solution and reservoir solution were mixed and the mixture was equilibrated against 0.1 ml reservoir solution in a 96-well sitting-drop Crystal-Quick plate (Greiner Bio-One). The crystallization conditions were optimized using the hanging-drop vapour-diffusion method by mixing 1.5 ml protein solution and 1.5 ml reservoir solution and equilibrating this mixture against 1 ml reservoir solution. All crystallizations were performed at 293 K.
Data collection and processing
All crystals of stoPCNA2-stoPCNA3 were transferred into a cryoprotectant solution composed of reservoir solution containing 40%(v/v) glycerol and flash-cooled in a nitrogen stream at 100 K. Two sets of diffraction data were collected from crystals which belonged to different space groups. Diffraction data from a crystal belonging to space group I222 were collected on a MicroMax 007 generator with an R-AXIS IV ++ image-plate detector (Rigaku) using an oscillation of 0.5 per frame, an exposure time of 10 min and a crystal-todetector distance of 230 mm. A total of 540 frames were collected. Diffraction data from a crystal belonging to space group P2 1 2 1 2 were collected with a DIP-6040 image-plate detector (MAC Science/ Bruker AXS) on SPring-8 beamline BL44XU (Harima, Japan) using an oscillation of 1.0 per frame, an exposure time of 4 s and a crystalto-detector distance of 500 mm. A total of 180 frames were collected. All diffraction data sets were processed, integrated and scaled with iMOSFLM (Leslie, 1992) and SCALA (Evans, 1997) from the CCP4 program suite (Collaborative Computational Project, Number 4, 1994) .
Results and discussion
Thin crystals of stoPCNA2-stoPCNA3 appeared from several crystallization conditions in the initial crystallization screening, in which ammonium sulfate and sodium citrate were common precipitants. To increase the thicknesses of the crystals, the crystallization conditions were optimized using 20À40 mg ml À1 protein and reservoir solutions with various pH values, precipitant concentrations and additives. The total number of optimization droplets was approximately 2000. Platelike crystals appeared after 1-2 weeks using two crystallization conditions: 20 mg ml À1 protein, 1.6 M ammonium sulfate, 0.1 M sodium acetate pH 5.0 (condition A; Fig. 1a ) and 20 mg ml À1 protein, 0.2 M sodium citrate, 18%(w/v) polyethylene glycol 3350, 0.1 M HEPES pH 7.0 (condition B; Fig. 1b ). X-ray diffraction was not detected from the crystals obtained using condition B, but was clearly observed from those obtained using condition A. SDS-PAGE analysis of the latter crystals revealed that they contained the stoPCNA2-stoPCNA3 complex (Fig. 1c) .
Two crystal forms were obtained using condition A. One crystal form belonged to the I-centred orthorhombic space group I222, with unit-cell parameters a = 91.1, b = 111.8, c = 170.9 Å . The other crystal form belonged to the primitive orthorhombic space group P2 1 2 1 2, with unit-cell parameters a = 91.1, b = 160.6, c = 116.6 Å . Table 1 summarizes the data-collection statistics.
Molecular-replacement searches using diffraction data from the I222 form were carried out for both stoPCNA2 and stoPCNA3 using the coordinates of ssoPCNAs (51% and 53% sequence identity to stoPCNA2 and stoPCNA3, respectively; PDB code 2izo; Doré et al., 2006) as search models. Calculations were performed with Phaser (McCoy et al., 2007) from the CCP4 suite. A search for stoPCNA3 was first performed and one clear solution (LLG = 404, Z score = 19.2) was obtained. Fixing the solution for stoPCNA3, a search for stoPCNA2 was conducted and an initial model with a good score (LLG = 964, Z score = 26.4) was obtained. Although a trimeric structure consisting of one stoPCNA2 molecule and two stoPCNA3 molecules was expected (Lu et al., 2008) , the initial model showed the presence of only one stoPCNA2 and one stoPCNA3 molecule in the asymmetric unit and the model generated by symmetry operations suggested a tetrameric ring-like structure consisting of two stoPCNA2 and two stoPCNA3 molecules. The models generated from the diffraction data of P2 1 2 1 2 form also indicated tetrameric structures. According to Matthews coefficient calculations (Matthews, 1968) , the crystals belonged to space groups I222 and P2 1 2 1 2, with Matthews coefficients V M of 3.96 and 3.90 Å 3 Da À1 , respectively. Precise model building and structure refinements are currently being performed. 
